Ask about this productRelated genes to: GHBP protein
- Gene:
- GHR NIH gene
- Name:
- growth hormone receptor
- Previous symbol:
- -
- Synonyms:
- GHBP
- Chromosome:
- 5p13.1-p12
- Locus Type:
- gene with protein product
- Date approved:
- 1989-06-30
- Date modifiied:
- 2018-02-13
Related products to: GHBP protein
Related articles to: GHBP protein
- Alzheimer's disease neuropathologic change (ADNC) classification identifies not/low and intermediate/high levels of neuropathology. Our goal was to assess how frequently a positive amyloid positron emission tomography (PET) scan indicates not/low ADNC and whether this autopsy finding can occur >10 years after a positive amyloid PET. - Source: PubMed
Burkett Brian JWiste Heather JJohnson Derek RBoeve Bradley FKantarci KejalPetersen Ronald CKnopman David SVemuri PrashanthiGraff-Radford JonathanLowe ValCogswell Petrice MPillai JaySchwarz Christopher GNguyen Aivi TMurray Melissa EDickson Dennis WJack Clifford R - Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing global health concern. This cross-sectional study aimed to evaluate the association between the AGAHR index [calculated as (alanine aminotransferase (ALT)×plasma fasting glucose (PFG)) to (aspartate aminotransferase (AST)×high-density lipoprotein cholesterol (HDL-C)) ratio] and MASLD. - Source: PubMed
Publication date: 2026/05/04
Wang ZiranShi YananLiu CunMa FanLv Zhou - This study aimed to evaluate the effects of dietary supplementation with the hexane fraction of Ulva fasciata extract (UH) on growth performance, immune responses, and antioxidant status in Nile tilapia (Oreochromis niloticus). Nile tilapia fingerlings (initial weight 3.13 ± 0.03 g) were fed diets supplemented with 0, 50, 100, or 150 mg kg⁻ UH for 60 days. The findings demonstrated that dietary supplementation with the hexane fraction of Ulva fasciata extract (UH150, UH100, and UH50) significantly increased final weight gain, specific growth rate, and improved feed conversion ratio compared to UH0 (control diet). According to the intestinal villi histomorphometric evaluation, fish that received UH exhibited improvements in villi length, goblet cell numbers, and intervillous spaces, particularly in UH100 (p < 0.05). However, UH150 demonstrated the most significant improvements in villi width. The highest WBC counts, phagocytic activity, lysozyme activity, superoxide dismutase and catalase activity-alongside normal ranges for hematological and biochemical parameters-were detected in fish that received 100 mgkg UH. The Ulva hexane fraction extract meals at 50, 100, and 150 mg kg triggered upregulation of growth hormone receptor (GHr), insulin-like growth factor (IGF-1), myostatin (MSTN), tumor necrosis factor alpha (TNF-α), heat shock protein 70 (HSP 70), fatty acid synthase (FAS), and lipoprotein lipase (LPL) with the best results being stated in UH150. In conclusion, UH dietary inclusion improved growth performance, feed utilization efficiency, and immune-physiological response of Nile tilapia. - Source: PubMed
Publication date: 2026/05/04
El-Nokrashy Asmaa MHassan Sara SElshafey Ahmed EMohamed Radi A - Cancer remains as the most feared human disease and embodies deep psychological and physical suffering (1). It is one of the unsolved medical problems nowadays and constitutes a heavy burden not only for the individual and his family but also for health systems worldwide (2). In this context, cancer prevention and early diagnosis and treatment is of cardinal importance; hence, identification of cancer risk factors in the genesis of human cancer is an urgent necessity. Among these deleterious influences, obesity and aberrantly increased growth hormone receptor (GHR) signaling have been identified as two of the most relevant factors in the etiology of malignancy (3, 4). Considering the above premises, attempts at effectively and safely treating patients with cancer are within the noblest aims in medicine and science. At present, radical surgery, radio and chemotherapy, targeted therapy, and immunotherapy are the basis for dealing with this widespread issue (5). Nevertheless, and especially in several types of cancer, all efforts are ineffective (6). In consequence, strategies to discover new medicines aimed at safely and effectively treating individuals affected by cancer are needed. Similarly, adjuvant methods aimed at making more effective use of standard therapies are required. Contextually, a new experimental approach to dealing with melanoma, liver cancer, pancreatic cancer, and cholangiocarcinoma, some of the most lethal malignancies in humans, has been developed based on the previous discovery of a GHR antagonist used for acromegaly and its mode of action (7, 8). Development of new drugs for cancer treatment is partially based on observations in humans who have a distinct phenotype that combines obesity -the most epidemiologic risk factor in cancer etiology- along with absent growth hormone receptor (GHR) signaling (4, 9). - Source: PubMed
Publication date: 2026/04/25
Guevara AlexandraKopchick John - Despite the clinical success of immune checkpoint inhibitors (ICIs), most patients with non-small cell lung cancer (NSCLC) fail to achieve durable responses due to intrinsic and acquired resistance. Growth hormone (GH) receptor (GHR) signaling has been implicated in tumor progression and therapy resistance, but its role in shaping anti-tumor immunity and chemo-immunotherapy response in NSCLC is unknown. To address this, syngeneic murine lung tumors were established in wild-type (WT) and GH antagonist transgenic (GHA) mice and treated with cisplatin, anti-PD-1 antibody, or their combination. Additionally, tumor growth was monitored longitudinally, while systemic and intratumoral insulin-like growth factor-1 (IGF-1) levels were quantified by ELISA. Tumor tissues were further analyzed by western blotting to assess immune checkpoint molecules, chemokine signaling components, and mediators of therapeutic resistance, and fibrotic remodeling was quantified using a hydroxyproline assay. High tumoral GHR expression was positively correlated with transcriptional signatures of therapy resistance, including ABC transporters, EMT markers, and ECM remodeling factors, and inversely associated with immune activation pathways. However, GHR antagonism in combination with cisplatin and anti-PD-1 therapy significantly suppressed tumor growth and enhanced therapeutic efficacy. Importantly, the combination of GHR blockade selectively increased PD-L1, PD-L2, and PD-1 expression, enhanced CXCL10-CXCR3 signaling, and downregulated the mediators of tumoral drug resistance and stromal remodeling. Therefore, we present the first indications that GHR signaling promotes immune suppression, therapy resistance, and fibrotic remodeling in NSCLC and support pharmacologic GHR antagonism as a novel strategy to sensitize tumors to chemo-immunotherapy. - Source: PubMed
Publication date: 2026/04/29
Ahmad ArshadBasu ReetobrataFyffe CadenGeiger ReeceWalsh ChristopherBrown Farrah NBashir BadraAlur Amrutha VarshiniList EdwardBerryman DarleneNeggers Sebastian J C M MKopchick John J